Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
- Main trialPhase 1
- “This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.”In the company’s words, NCT07503808 on ClinicalTrials.gov
Other drugs for Esophageal Squamous Cell Carcinoma
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- DurvalumabAstraZeneca · Phase 3
- Ifinatamab DeruxtecanDaiichi Sankyo · Phase 3
- MHB088CQilu Pharmaceutical · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- EnlonstobartCSPC · Phase 3
Coming up1
- 30 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Jul 2027 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026